<DOC>
	<DOCNO>NCT02659293</DOCNO>
	<brief_summary>This Phase 3 randomize trial carfilzomib , lenalidomide , dexamethasone versus lenalidomide alone stem-cell transplant multiple myeloma , eligible subject complete autologous stem cell transplant symptomatic myeloma consider lenalidomide maintenance .</brief_summary>
	<brief_title>Trial Carfilzomib , Lenalidomide , Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant Multiple Myeloma</brief_title>
	<detailed_description>Primary Objective : - To compare progression free survival Kyprolis ( Carfilzomib ) , Revlimid ( lenalidomide ) , Dexamethasone ( KRd ) arm lenalidomide arm Secondary Objectives - To determine rate minimal residual negative disease ( MRD ) 6 12 month randomization - To compare efficacy ( rate partial response , good partial response , complete response , stringent complete response ) KRd vs. Lenalidomide alone randomization</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients complete single autologous stem cell transplant completion 2 induction regimen ( exclude dexamethasone alone ) least stable disease first 100 day stem cell transplantation . 2 . Patients must within 12 month initiation induction therapy must 2 prior induction regimen . 3 . Bone marrow specimen require study entry ; available DNA sample use calibration step MRD evaluation gene sequence . 4 . Males females ≥ 18 year age 5 . ECOG performance status 01 6 . Adequate hepatic function , bilirubin ≤ 1.5 x ULN aspirate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 x ULN 7 . ANC ≥ 1.0 x 109/L , hemoglobin ≥ 8 g/dL , platelet count ≥ 75 x 109/L . 8 . Calculated creatinine clearance ( CockcroftGault ) ≥ 50 ml/min serum creatinine 2 mg/dL 9 . Females childbearing potential ( FCBP ) must 2 negative pregnancy test ( sensitivity least 50 mIU/mL ) prior initiate lenalidomide . The first pregnancy test must perform within 1014 day second pregnancy test must perform within 24 hour lenalidomide prescribe Cycle 1 ( prescription must fill within 7 day ) . 10 . FCBP must agree use 2 reliable form contraception simultaneously practice complete abstinence heterosexual intercourse follow time period relate study : 1 ) least 28 day start lenalidomide ; 2 ) participate study ; 3 ) least 28 day discontinuation study . UCM IRB CRd vs. R Version 1.0 Page 11 11 . Male subject must agree use latex condom sexual contact female childbearing potential participate study least 28 day follow discontinuation study even undergone successful vasectomy . 12 . All study participant US must consent registered mandatory Revlimid REMS® program willing able comply requirement Revlimid REMS® . 13 . Voluntary write informed consent 1 . Patients complete single autologous stem cell transplant completion 2 induction regimen ( exclude dexamethasone alone ) least stable disease first 100 day stem cell transplantation . 2 . Patients must within 12 month initiation induction therapy must 2 prior induction regimen . 3 . Bone marrow specimen require study entry ; available DNA sample use calibration step MRD evaluation gene sequence . 4 . Males females ≥ 18 year age 5 . ECOG performance status 01 6 . Adequate hepatic function , bilirubin ≤ 1.5 x ULN aspirate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 x ULN 7 . ANC ≥ 1.0 x 109/L , hemoglobin ≥ 8 g/dL , platelet count ≥ 75 x 109/L . 8 . Calculated creatinine clearance ( CockcroftGault ) ≥ 50 ml/min serum creatinine 2 mg/dL 9 . Females childbearing potential ( FCBP ) must 2 negative pregnancy test ( sensitivity least 50 mIU/mL ) prior initiate lenalidomide . The first pregnancy test must perform within 1014 day second pregnancy test must perform within 24 hour lenalidomide prescribe Cycle 1 ( prescription must fill within 7 day ) . 10 . FCBP must agree use 2 reliable form contraception simultaneously practice complete abstinence heterosexual intercourse follow time period relate study : 1 ) least 28 day start lenalidomide ; 2 ) participate study ; 3 ) least 28 day discontinuation study . UCM IRB CRd vs. R Version 1.0 Page 11 11 . Male subject must agree use latex condom sexual contact female childbearing potential participate study least 28 day follow discontinuation study even undergone successful vasectomy . 12 . All study participant US must consent registered mandatory Revlimid REMS® program willing able comply requirement Revlimid REMS® . 13 . Voluntary write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>stem-cell transplant</keyword>
	<keyword>Symptomatic myeloma</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>carfilzomib</keyword>
	<keyword>dexamethasone</keyword>
</DOC>